All In Biotech

Drug Trial Radar · NCT05145218

A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian Cancer

A Multicenter, Randomized, Open, Parallel Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of TQB2450 Injection Combined With Androtinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment in the Treatment of Recurrent Platinum-resistant Ovarian Cancer

Last checked: Nov 19, 2026Latest source record: Dec 8, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 405 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

405

Planned (sponsor's estimate)

Start

Sep 28, 2021

Primary completion

Oct 2024

Study completion Dec 2024

Sponsor

Sponsor type
Industry
First posted
Dec 6, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A clinical study to evaluate the efficacy and safety of TQB2450 injection combined with Anlotinib Hydrochloride capsules versus weekly treatment with paclitaxel of recurrent platinum-resistant ovarian cancer.A total of 405 subjects will be enrolled.

Conditions

  • Recurrent Platinum-resistant Ovarian Cancer

Interventions

  • Anlotinib Hydrochloride CapsulesDrug

    Anlotinib Hydrochloride is a multi-target tyrosine kinase inhibitor.

  • Paclitaxel injectionDrug

    Paclitaxel is a novel anti-microtubule agent.

  • TQB2450 injectionDrug

    TQB2450 is a programmed cell death protein 1 (PD-1) humanized monoclonal antibody.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease progression-free survival(PFS) evaluated by Independent Review Committee(IRC)Time frame: Baseline up to two years
  2. Overall survival (OS)Time frame: Baseline up to two years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

  • AnYang Tumor Hospital

    Anyang, Henan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.